via epilepsyu.com
Giving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell today (Thursday).
Francis Crick Institute researchers, funded by Cancer Research UK, have shown that skin, breast and bowel cancer cells often produce large amounts of prostaglandin E2 (PGE2). This molecule dampens down the immune system’s normal response to attack faulty cells, which helps cancer to hide. It is a trick that allows the tumour to thrive and may explain why some immunotherapy treatments have not been as effective as hoped.
Aspirin is part of a group of molecules called COX inhibitors, which stop the production of PGE2 and help reawaken the immune system. Combining immunotherapy with aspirin or other COX inhibitors substantially slowed bowel and melanoma skin cancer growth in mice, compared to immunotherapy alone*.
Study author Professor Caetano Reis e Sousa, senior group leader at the Francis Crick Institute, said: “We’ve added to the growing evidence that some cancers produce PGE2 as a way of escaping the immune system. If you can take away cancer cells’ ability to make PGE2 you effectively lift this protective barrier and unleash the full power of the immune system.
“Giving patients COX inhibitors like aspirin at the same time as immunotherapy could potentially make a huge difference to the benefit they get from treatment. It’s still early work but this could help make cancer immunotherapy even more effective, delivering life-changing results for patients.”
Read more: Aspirin could hold the key to supercharged cancer immunotherapy
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- An mRNA Vaccine for Cancer Immunotherapyon February 26, 2021 at 2:02 am
Researchers have developed a hydrogel that, when injected into mice with melanoma, slowly released RNA nanovaccines that shrank tumors and kept them from metastasizing.
- Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Canceron February 25, 2021 at 11:00 am
According to investigators, study findings could help guide treatment decisions and future research, as well as suggest new biomarkers for exploration.
- Dr. Wenham on Rationale for Novel Immunotherapy Combos in Ovarian Canceron February 24, 2021 at 3:09 pm
Robert Wenham, MD, MS, FACOG, FACS, discusses novel immunotherapy combinations for the treatment of patients with ovarian cancer.
- An mRNA nanovaccine for cancer immunotherapyon February 24, 2021 at 6:11 am
Researchers have developed a graphene oxide hydrogel that, when injected into mice with melanoma, slowly released RNA nanovaccines that shrank tumors and kept them from metastasizing.
- Cancer immunotherapy market is expected to grow CAGR of around 10.6% during the forecast period 2019 to 2026on February 24, 2021 at 3:55 am
The global cancer immunotherapy market is expected to grow at a noteworthy CAGR of around 10.6% during the forecast period 2019 to 2026 The Cancer Immunotherapy Market size is poised to hit around US$ ...
- Oncorus Inc.: Undervalued Cancer Viral Immunotherapy Opportunityon February 23, 2021 at 7:01 am
Phase 1 monotherapy data for ONCR-177 in cancers like breast, melanoma and head and neck cancer is expected in the second half this year. I do much more than just articles at Vasuda Healthcare ...
- FDA Grants Fast Track Designation to GEN-1 Immunotherapy for Treatment of Advanced Ovarian Canceron February 22, 2021 at 1:02 pm
Celsion Corporation announced that fast track designation was granted to their immunotherapy, GEN-1, to treat patients with advanced stage III or IV ovarian cancer.
- Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapyon February 19, 2021 at 8:13 pm
Despite great success in cancer immunotherapy, immune checkpoint-targeting drugs are not the most popular weapon in the armory of cancer therapy. Accumulating evidence suggests that the tumor immune ...
- Improving Cancer Immunotherapy by Blocking Glucose Supplyon February 17, 2021 at 5:00 am
Memorial Sloan Kettering researchers reported that a way to improve immunotherapy is by altering immune cells' access to sugar.
- Cancer Tricks Immune Cells, Immunotherapy Can Take Advantageon February 16, 2021 at 5:31 am
A paper published today in Nature shows how chemicals in the areas surrounding tumors—known as the tumor microenvironment—subvert the immune system and ...
via Bing News
